Deputy Director of the Duke Cancer Institute and Professor of Medicine at Duke University School of Medicine
Pro to the question "Should Marijuana Be a Medical Option?"
"The use of marijuana as a medicine is remarkably uncontroversial at the bedside of a cancer patient or a child suffering from convulsions who might be helped...
The Compassionate Care Act, passed by the New York State Legislature last month and signed into law by Gov. Andrew Cuomo on July 5, , introduces simple yet profound reforms by banning marijuana smoking and mandating individual dosing of medical cannabis in all other forms, such as capsules and vaporization. By treating medical marijuana like other medicines, New York shifted the debate into the mainstream of modern medicine and set a much-needed national standard of care...
Metered dosing is the standard of care in modern medicine, allowing doctors to prescribe precise amounts based on the patient's response, and reducing the chance of adverse drug interactions...
Cannabis produced in metered doses is easily tested for contaminants, and the potency of all active ingredients, for instance, and sterilized for safety—essential public-health safeguards...
[T]he introduction of smokeless cannabis in dosage form will immediately ease human pain and suffering and help to move medical marijuana from the underground economy to the mainstream of the nation's health-care system."
"New York Does Medical Marijuana Right," Wall Street Journal, July 7, 2014
Experts Individuals with MDs, PhDs, JDs, or equivalent advanced degrees in fields relevant to medical marijuana. Also top-level government officials (such as foreign leaders, US presidents, Founding Fathers, Supreme Court Justices, members of legislative bodies, cabinet members, military leaders, etc.) with positions relevant to medical marijuana issues.
Involvement and Affiliations:
Deputy Director, Duke Cancer Institute, 2012-present
Professor, Medicine, Duke University School of Medicine
Professor, Pharmacology, Cancer Biology, Community and Family Medicine, Duke University
Executive Director, George Washington University Cancer Institute, 1988-2012
Founding Director, Molecular and Cellular Oncology PhD Program, George Washington University Medical Center
Former Vivian Gill Distinguished Professor of Oncology, George Washington University
Former Professor of Pharmacology, Genetics, and Urology, School of Medicine and Health Sciences, George Washington University
Former Professor of Environmental and Occupational Health, George Washington University School of Public Health and Health Services
Post-doctoral fellow, University of Southern California Norris Comprehensive Cancer Center, 1985-1988
Former Rosalie B. Hite Graduate Fellowship, Cancer Research, MD Anderson Cancer Institute.
Recipient, Distinguished Public Service Award, Breast Cancer Resource Committee
Recipient, Stoddard Community Service Award, Family and Child Services of Washington, DC
PhD, Pharmacology and Molecular Oncology, Graduate School of Biomedical Science, University of Texas Health Science Center, 1985
Cowritten with K.P. Nickens, J.D. Wikstrom, O.S. Shirihai, and S. Ceryak, "A Bioenergetic Profile of Non-transformed Fibroblasts Uncovers a Link between Death-resistance and Enhanced Spare Respiratory Capacity," Mitochondrion, Nov. 2013
Cowritten with M.E. Bensink, S.D. Ramsey, T. Battaglia, et al., "Costs and Outcomes Evaluation of Patient Navigation after Abnormal Cancer Screening: Evidence from the Patient Navigation Research Program," Cancer, Feb. 2013
Cowritten with H.J. Hoffman, N.L. LaVerda, H.A. Young, P.H. Levine, L.M. Alexander, et al., "Patient Navigation Significantly Reduces Delays in Breast Cancer Diagnosis in the District of Columbia," Cancer Epidemiology, Biomarkers and Prevention, Oct. 2012
Cowritten with G.C. Kost, S.S. Wise, A.L. Holmes, J.P. Wise, S. Ceryak, "Protein Tyrosine Phosphatase (PTP) Inhibition Enhances Chromosomal Stability after Genotoxic Stress: Decreased Chromosomal Instability (CIN) at the Expense of Enhanced Genomic Instability (GIN)?," Mutation Research, July 2012
Cowritten with K.P. Nickens, Y. Han, H. Shandilya, A. Larrimore, G.F. Gerard, E. Kaldjian, S. Ceryak, "Acquisition of Mitochondrial Dysregulation and Resistance to Mitochondrial-mediated Apoptosis after Genotoxic Insult in Normal Human Fibroblasts: A Possible Model for Early Stage Carcinogenesis," Molecular Cell Research, Feb. 2012
Has authored over 100 scientific journal articles and book chapters